Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for...
September 30 2020 - 7:00AM
Business Wire
Principal Investigator Prof. Rifaat Safadi
to present Namodenoson’s Phase II results at highly prestigious
scientific conference for liver diseases
Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver
diseases, today announced the Scientific Program Committee of the
American Association for the Study of Liver Diseases (AASLD) has
selected Can-Fite’s late-breaking abstract for oral presentation at
The Liver Meeting Digital Experience™ 2020. The presentation
titled, “A Phase 2, Randomized, Double-Blind, Placebo-Controlled
Dose-Finding Study Of The Efficacy And Safety Of Namodenoson
(CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating
Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic
Steatohepatitis (NASH)” will be delivered on Sunday, November 15,
2020, by the Principal Investigator of the Phase II study, Dr.
Rifaat Safadi, Head of the Liver Unit, Gastroenterology and Liver
Diseases, Division of Medicine at Hadassah Medical Center,
Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic
Syndrome at Hebrew University in Israel. The AASLD’s The Liver
Meeting® will be held virtually on November 13 through 16,
2020.
“We are honored and pleased to be selected by the AASLD’s
Scientific Program Committee to present these late-breaking
findings. Our Phase II data were very compelling and we look
forward to Dr. Safadi sharing these results with the leading
clinicians and researchers in the field of liver diseases. The
pressing need for a safe and effective treatment for NAFLD and NASH
underscores the importance of the scientific community advancing a
treatment towards market,” stated Can-Fite CEO Dr. Pnina
Fishman.
Can-Fite’s Phase II NAFLD/NASH study achieved its efficacy and
safety endpoints in a dose dependent and statistically significant
manner.
The NASH market is projected to reach at least $35 billion by
2025. There are currently no other treatment options approved for
this growing unmet need.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, liver, inflammatory disease and
COVID-19. The Company's lead drug candidate, Piclidenoson, is
currently in Phase III trials for rheumatoid arthritis and
psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a
Phase III trial for hepatocellular carcinoma (HCC), the most common
form of liver cancer, and successfully achieved its primary
endpoint in a Phase II trial for the treatment of non-alcoholic
steatohepatitis (NASH). Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction. These drugs have
an excellent safety profile with experience in over 1,500 patients
in clinical studies to date. For more information please visit:
www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or
“anticipate” or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite’s authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite’s actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite’s actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses
and needs for additional capital to fund our operations and our
inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working
capital needs; the initiation, timing, progress and results of our
preclinical studies, clinical trials and other product candidate
development efforts; our ability to advance our product candidates
into clinical trials or to successfully complete our preclinical
studies or clinical trials; our receipt of regulatory approvals for
our product candidates, and the timing of other regulatory filings
and approvals; the clinical development, commercialization and
market acceptance of our product candidates; our ability to
establish and maintain strategic partnerships and other corporate
collaborations; the implementation of our business model and
strategic plans for our business and product candidates; the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
our ability to operate our business without infringing the
intellectual property rights of others; competitive companies,
technologies and our industry; statements as to the impact of the
political and security situation in Israel on our business; and
risks and other risk factors detailed in Can-Fite’s filings with
the SEC and in its periodic filings with the TASE. In addition,
Can-Fite operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors
beyond its control. Can-Fite does not undertake any obligation to
publicly update these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200930005336/en/
Can-Fite BioPharma Motti Farbstein info@canfite.com
+972-3-9241114
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Sep 2023 to Sep 2024